Click here to learn more or to register for the International Symposium on Malignant Mesothelioma.
[youtube=http://www.youtube.com/watch?v=AeaZWg50vKg]
FDA Approves KEYTRUDA® (pembrolizumab) Plus Pemetrexed and Platinum Chemotherapy as First-Line Treatment for Patients with Unresectable or Metastatic Malignant Pleural Mesothelioma
For patients with MPM (Malignant Pleural Mesothelioma), the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA® (pembrolizumab) as a first-line treatment when combined with
